KNDS, Triton Reach Agreement After Spat Over Renk Stake
Triton on Monday said in a statement it would transfer 9,166,667 shares in the settlement, which increases KNDS's current stake in Renk to 15.8%. KNDS had sought to expand its 6.7% stake to 25% before the conflict with Triton.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Oliver Glasner issues clear Liverpool transfer verdict before Wembley clash - 'Clearly'
Liverpool is set to start the 2025/26 season with the Community Shield against Crystal Palace, the 2025 FA Cup champions who upset Manchester City 1-0 in the final. Outside of finalizing a move for one last attacker — seemingly Alexander Isak from Newcastle — and some center-back cover, the Reds have likely finished their summer business. Ahead of Sunday's clash — a game where Virgil van Dijk and Alisson Becker will likely return — Palace manager Oliver Glasner said "you can clearly see a club's ambitions in the transfer market. And it seems that Liverpool FC isn't satisfied with just winning the English league; I think they want to win the Champions League." READ MORE: Liverpool handed double boost before Community Shield as Virgil van Dijk spotted READ MORE: Darwin Nunez showed his true colors with trophy remark as Liverpool transfer exit looms Meanwhile, his Eagles have spent more time trying to win an appeal wth UEFA to reclaim their spot in the 2025/26 Europa League taken from them due to joint ownership issues with Olympique Lyon. At the time of writing, Palace is set to the play in the Conference League. Who has Liverpool signed? The Reds took two players from Bayer Leverkusen in midfielder Florian Wirtz (€125.00m, $156 million) and wing-back Jeremie Frimpong (€40 million, $46.5 million). Liverpool secured striker Hugo Ekitike from Eintracht Frankfurt for €95 million ($110 million) and left-back Milos Kerkez from Bournemouth for €46.9 million ($55 million). Even reserve goalkeeper Armin Pesci was drafted from Paskas AFC for €1.8 million ($2 million). 'They've been playing at this level for years, so I have to say I was a bit surprised that they were so active, but of course it also shows their ambitions," Glasner added. "They obviously saw that we needed to add one or two things to the squad, and they made that very clear and explicit early on this summer.' His Palace side has been far more tepid in the market, having only inked fullback Borna Sosa from Ajax (for a bargin fee) and goalkeeper Walter Benetiz from PSV (free transfer). Glasner joined the Eagles in the second half of the 2024 season and boasts an impressive 45.54% win percentage with the club across 61 matches. In addition to leading Palace to their first trophy, the club's 53 points last season were their most ever in a Premier League season. READ MORE: Jurgen Klopp shared Darwin Nunez warning immediately after signing Liverpool striker READ MORE: How Liverpool could line up with Bradley Barcola in four-way attacking dream Glasner has been successful wherever he's gone. He was named both director of sport and manager at LASK while they played in the Austrian second tier and had them second in the first division within a few seasons. He led German powerhouse Wolfsburg to the Champions League in 2021 for the first time in a decade and then won the Europa League with Eintracht Frankfurt a season later. Glasner also weighed in on the 2025/26 title race. 'Four or five clubs have invested heavily again. If I take City, over €300 million in 2025, Liverpool similarly, I think Arsenal not far behind, Chelsea exactly the same, so you can see that they want to win the Premier League, they want to win the Champions League," he said.
Android Authority
20 minutes ago
- Android Authority
Galaxy Tab S11 leak spills all the details, and it could be good news for US users
Earlier this year, we found evidence that Samsung was working on at least three Android tablets. These tablets would include two successors to the Galaxy Tab S10 and an S10 Lite model. Last month, a Samsung executive confirmed to Android Authority that the Galaxy Tab S11 series is on the way and that the release would follow 'our traditional cadence.' A new leak may have now revealed the specifications, launch window, and European prices. According to a report from Dealabs , the Galaxy Tab S11, S11 Ultra, and S10 Lite will have Wi-Fi and 5G models. The Galaxy Tab S11 series will reportedly be available in Gray and Silver. Meanwhile, the Galaxy Tab S10 Lite is said to have three color options: Gray, Silver, and Red. In addition to these details, the leak revealed the following specs for all three tablets: As mentioned earlier, we were told that the launch of the Galaxy Tab S11 would follow Samsung's traditional cadence. Last year, the company launched the Galaxy Tab S10 in September, meaning we should expect a release that month. When exactly in September is unknown, but Dealabs suggests that the launch should happen between September 4 and September 5. It's still unclear what the prices will be in the US, but this leak does give us the prices in Europe. Samsung Galaxy Tab S11 12 GB / 128 GB: Wi-Fi: €899 ($1,047) / Wi-Fi + 5G: €1,049 ($1,221) 12 GB / 256 GB: Wi-Fi: €959 ($1,116) / Wi-Fi + 5G: €1,109 ($1,291) 12 GB / 512 GB: Wi-Fi: €1,079 ($1,256) Samsung Galaxy Tab S11 Ultra 12 GB / 256 GB: Wi-Fi: €1,339 ($1,559) / Wi-Fi + 5G: €1,489 ($1,733) 12 GB / 512 GB: Wi-Fi: €1,459 ($1,698) / Wi-Fi + 5G: €1,609 ($1,872) 16 GB / 1 TB: Wi-Fi: €1,759 ($2,047) Samsung Galaxy Tab S10 Lite 6 GB / 128 GB: Wi-Fi: €399 ($464) / Wi-Fi + 5G: €459 ($523) 8 GB / 256 GB: Wi-Fi: €469 ($546) / Wi-Fi + 5G: €529 ($616) The prices for the Galaxy Tab S11 Ultra appear to mirror the launch prices for last year's Galaxy Tab S10 Ultra. That bodes well for the US, as it could mean that Samsung has no plans to hike up prices. But we'll still have to wait for the official announcement to know for sure.
Newsweek
21 minutes ago
- Newsweek
Europe to Escape New Trump Pharmaceutical Tariffs
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The trade deal struck between the U.S. and the European Union will allow the EU to escape the latest tariffs President Donald Trump has threatened to place on pharmaceuticals, Newsweek understands. On Tuesday, Trump said he was planning to place a "small tariff" on drug imports that will eventually grow to 250 percent. But thanks to the pact agreed in late July, the EU will see its pharmaceuticals hit with only a 15-percent tariff, far below the rates other countries may encounter. Why It Matters This aligns with the terms of the deal published by the White House, and European Commission President Ursula von der Leyen's assurance that pharmaceuticals were among the sectors for which the 15 percent rate represented a firm "ceiling." However, Trump's comments on new pharmaceutical tariffs sparked uncertainty over whether these would apply on top of agreed rates, triggering the share prices of many European drug companies to plummet. What To Know During an interview with CNBC on Tuesday, Trump said he was planning to impose new sectoral duties on pharmaceuticals, like the tariffs already placed on steel, aluminum and auto imports. "On pharmaceuticals, we'll be putting a initially small tariff on pharmaceuticals," Trump said. "But in one year, one and a half years maximum, it's going to go to 150 percent, and then it's going to go to 250 percent, because we want pharmaceuticals made in our country." The president went on to say that he would be announcing specifics "within a week or so," and that this new tariff would be separate from country-specific duties. President Donald Trump pauses while speaking in the Oval Office, Wednesday, Aug. 6, 2025, in Washington. President Donald Trump pauses while speaking in the Oval Office, Wednesday, Aug. 6, 2025, in Washington. Alex Brandon/AP Photo The statement rocked drug companies worldwide, including those in the EU. Shares in Denmark-based Novo Nordisk fell more than 5 percent over the course of Wednesday's trades, with those in Germany-based Bayer AG dropping by nearly 10 percent. According to The Guardian, the Europe's Stoxx Health Care index, which tracks the performance of major health care sector firms across Europe, dropped to its lowest level since mid-April. EU exports of medicinal and pharmaceutical products to the U.S. totaled over $100 billion for the first time in 2024, according to Eurostat, equating to 38 percent of its total exports in this area. What People Are Saying White House deputy press secretary Kush Desai previously told Newsweek: "President Donald Trump is committed to safeguarding our national and economic security, and that includes ensuring that Americans are never again left in the lurch as they were during the COVID era when shortages of imported drugs and other lifesaving medical equipment put lives at risk." The White House, in a fact sheet published following the EU trade deal, said: "As part of President Donald Trump's strategy to establish balanced trade, the European Union will pay the United States a tariff rate of 15%, including on autos and auto parts, pharmaceuticals, and semiconductors. However, the sectoral tariffs on steel, aluminum, and copper will remain unchanged—the EU will continue to pay 50% and the parties will discuss securing supply chains for these products." What Happens Next? While the U.S. has officially handed the bloc a 15 percent tariff on most of its imports as of Thursday, certain disagreements remain over the terms of the EU trade deal. Some member nations have framed this as an informal understanding rather than a finalized pact. "This is not the end of the story, the negotiation has to continue," French President Emmanuel Macron told his ministers shortly after the deal was signed, according to Euractiv. Meanwhile, Trump told CNBC that if the EU fails to follow through on the investment commitments outlined in the deal, then he will hike their tariff rates to 35 percent. Regarding the 250-percent tariff on pharmaceuticals, White House deputy press secretary Kush Desai told Newsweek that no decisions should be considered final "until officially announced by President Donald Trump."
